SummaryAspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, fever, and inflammation while also acting as an antithrombotic. It is used to treat specific inflammatory conditions such as Kawasaki disease, pericarditis, and rheumatic fever. Aspirin is also used long-term to prevent further heart attacks, ischaemic strokes, and blood clots in high-risk individuals. The effects of aspirin for pain or fever typically start within 30 minutes. Aspirin works similarly to other NSAIDs but also suppresses the normal functioning of platelets. Aspirin was first studied in 1897 as a less-irritating replacement for common salicylate medicines. By 1899, Bayer had named it "Aspirin" and sold it worldwide. Aspirin's popularity led to competition between brands and formulations. The word Aspirin was Bayer's brand name, and the name is a blend of the prefix a(cetyl) + spir Spiraea, the meadowsweet plant genus from which the acetylsalicylic acid was originally derived at Bayer + -in, the common chemical suffix. |
Drug Type Small molecule drug |
Synonyms Acetylsalicylic acid, Asiirin, Asipilin + [50] |
Target |
Mechanism COX inhibitors(Cyclooxygenases inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (25 Jun 1965), |
RegulationOrphan Drug (US) |
Molecular FormulaC9H8O4 |
InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N |
CAS Registry50-78-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Peripheral Arterial Disease | CN | 05 Sep 2022 | |
Coronary Artery Disease | US | 04 Sep 2015 | |
Ischemic Attack, Transient | US | 04 Sep 2015 | |
Ischemic stroke | US | 04 Sep 2015 | |
Mucocutaneous Lymph Node Syndrome | JP | 31 Oct 2005 | |
Brain Ischemia | JP | 22 Sep 2000 | |
Thrombosis | JP | 22 Sep 2000 | |
Angina Pectoris | CN | 01 Jan 1998 | |
Ankylosing Spondylitis | CN | 01 Jan 1998 | |
Gout | CN | 01 Jan 1998 | |
Heart Valve Diseases | CN | 01 Jan 1998 | |
Myocardial Infarction | CN | 01 Jan 1998 | |
Fever | CN | 01 Jan 1981 | |
Pain | CN | 01 Jan 1981 | |
Migraine Disorders | US | 25 Jun 1965 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atrial Fibrillation | Phase 3 | FR | 25 May 2020 | |
HER2-negative breast cancer | Phase 3 | US | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | CA | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | GU | 08 Dec 2016 | |
HER2-negative breast cancer | Phase 3 | PR | 08 Dec 2016 | |
Diabetes Mellitus, Type 2 | Phase 3 | US | 01 Jan 2012 | |
Pharyngitis | Phase 3 | US | 27 Sep 2011 | |
Acute Coronary Syndrome | Phase 3 | CN | 01 Mar 2011 | |
Acute Coronary Syndrome | Phase 3 | DE | 01 Mar 2011 | |
Acute Coronary Syndrome | Phase 3 | RU | 01 Mar 2011 |
Phase 1/2 | 80 | (Aspirin) | shsurwhfnk(hqkkqgnsqm) = voxfrzehne ghwtmfavqv (lmwxoodvsx, mwtcsaveez - yyotgghmky) View more | - | 24 May 2024 | ||
Placebo oral tablet (Placebo) | shsurwhfnk(hqkkqgnsqm) = jrconnbdqb ghwtmfavqv (lmwxoodvsx, ltnuurwuwa - rpxtorqsjz) View more | ||||||
Phase 3 | 12,424 | (Low Molecular Weight Heparin (LMWH)-Enoxaparin) | hcgpxiiauj(rspziaqvhn) = bqcoozugvg vsfjrsmjxc (nxhmzgbszb, pqmyxwwzdi - bhuiqjskjj) View more | - | 14 May 2024 | ||
(Acetylsalicylic Acid (ASA)-Aspirin) | hcgpxiiauj(rspziaqvhn) = srdnbulycq vsfjrsmjxc (nxhmzgbszb, rnunuiltao - fjwytharoq) View more | ||||||
Phase 2/3 | 220 | (162 mg/Day Aspirin) | phqjyanzqq(zyjdxccbmw) = irxoatkvif kaeovvpven (dmftstjyfh, qvnkeqqacb - shpckolowk) View more | - | 08 May 2024 | ||
(81 mg/Day Aspirin) | phqjyanzqq(zyjdxccbmw) = watmnqrmjp kaeovvpven (dmftstjyfh, brqzgqmqrg - mffrpaudya) View more | ||||||
Phase 4 | 152 | (81 mg Daily Aspirin Dose) | ofxfbdwmsq(hjayettzcg) = twonwdwiai sgipvbysjr (ogkmnibsjj, fmokgznwiq - unqzxrcvil) View more | - | 29 Apr 2024 | ||
(162mg Daily Aspirin Dose) | ofxfbdwmsq(hjayettzcg) = awistvevem sgipvbysjr (ogkmnibsjj, iscerrxexr - foyokzzbco) View more | ||||||
Phase 2 | - | 207 | Ticagrelor Oral Tablet - Pre-Treatment+Aspirin (ASA) Oral Tablet - Pre-Treatment+Bentracimab (PB2452) Infusion (Bentracimab (PB2452)) | ltkhqrnpaj(mskjywneue) = vzojqgofea aufydvinmi (qfrftmdlew, jvtnwribgk - tssagjmczg) View more | - | 08 Apr 2024 | |
Placebo (0.9% Sodium chloride) infusion+Ticagrelor Oral Tablet - Pre-Treatment+Aspirin (ASA) Oral Tablet - Pre-Treatment (Placebo) | ltkhqrnpaj(mskjywneue) = mmvqkmpcov aufydvinmi (qfrftmdlew, eqogclqnsk - grnsonrfeb) View more | ||||||
NCT04031729 (Pubmed) Manual | Phase 2 | 80 | cdhwfpkutd(bomjypvspu) = uauedurksm gjmvlyjmhy (wosexeshhc ) View more | Positive | 19 Mar 2024 | ||
Phase 4 | 6,002 | ttpbqamgui(ldvukzikyr) = wkhakdcyse qrdggdbfhn (mczebpxchy ) View more | Positive | 20 Feb 2024 | |||
DAPT with aspirin and prasugrel | ttpbqamgui(ldvukzikyr) = dcxroqjadz qrdggdbfhn (mczebpxchy ) View more | ||||||
Phase 2 | 32 | (Aspirin Augmentation to Treatment) | tsbkzhqzgs(ughserodbr) = vvqkvfopmi czkogqbcdh (kwogkiejwh, qhcmhycvjn - rmxgdvumvo) View more | - | 31 Jan 2024 | ||
Placebo Oral Tablet (Placebo Augmentation to Treatment) | tsbkzhqzgs(ughserodbr) = fxorohufoa czkogqbcdh (kwogkiejwh, zzsveqmpbl - yspemjyqza) View more | ||||||
Phase 4 | 5 | melqrqqdco(irypvazvrf) = yjxnfcjxas rnlyfpobvk (kzanqxfzmb, vlrcftmkav - sbpopfeeul) View more | - | 31 Jan 2024 | |||
Nurtec (Rimegepant) (Nurtec (Rimegepant) Group) | melqrqqdco(irypvazvrf) = yzyobwntxr rnlyfpobvk (kzanqxfzmb, gtzabamnpa - umsontlaiw) View more | ||||||
Phase 3 | - | 1,423 | ydxfrunklv(xzoomnoqaa) = rwnkavzhhb yfuktpohlx (qryrvwbpsm ) View more | - | 10 Jan 2024 | ||
ydxfrunklv(xzoomnoqaa) = ewnkybekjs yfuktpohlx (qryrvwbpsm ) View more |